Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Phase 1

Recruiting

• Conditions: Solid Tumor
• Interventions: Drug: D-1553; Drug: IN10018

• Registration Number: NCT05379946
• Lead Sponsor: InventisBio Co., Ltd

Brief Summary

This is a phase 1/2, open label study of D-1553 in combination with IN10018 to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2022-05-13
• Study First Submitted QC: 2022-05-13
• Study First Posted: 2022-05-18
• Study Start: 2022-10-12
• Status Verified: 2023-10
• Last Update Submitted: 2024-10-11
• Last Update Posted: 2024-10-14
• Primary Completion: 2025-06-30
• Study Completion: 2025-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 92

Inclusion Criteria

• Subject with histologically proven, locally advanced, unresectable and/or metastatic solid tumor, for which no standard treatment is available or the subject is refractory to or intolerant of existing standard treatment.
• Subject has KRasG12C mutation in tumor tissue or other biospecimens (only for phase1b) containing cancer cells or DNA. Historical, local laboratory result (up to 5 years prior to this study) can be used.
• Subject has tumor type requirement as follows: advanced or metastatic solid tumors including NSCLC and CRC.
• Subject has measurable disease according to RECIST, v1.1

Read More

Exclusion Criteria

Subject with unstable or progressive central nervous system (CNS) metastases.

• Subject with acute myocardial infarction, severe/unstable angina; or with cardiac insufficiency of New York Heart Association Functional Classification Grade 2 or above.
• Subject has corrected QT interval using Fridericia's formula (QTcF) prolongation at rest, where the mean QTc interval is > 480 msec based on triplicate measurements of electrocardiogram (ECG).
• Subject with stroke or other severe cerebrovascular diseases within 12 months before enrollment;
• Subject with interstitial lung disease or acute lung infection not yet recovered including but not limited to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection;
• Subject is pregnant or lactating.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Phase 1b Dose escalation of D-1553 plus IN10018	D-1553	Phase 1b will evaluate up sequential cohorts with different doses of IN10018 together with D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation.
Phase 2 Doseexpansion of D-1553 plus IN10018	D-1553	Phase 2 will include more subjects to further evaluate the safety and efficacy of D-1553 in combination with IN10018 in patients with solid tumors with KRasG12C mutation.
Phase 1b Dose escalation of D-1553 plus IN10018	IN10018	Phase 1b will evaluate up sequential cohorts with different doses of IN10018 together with D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation.
Phase 2 Doseexpansion of D-1553 plus IN10018	IN10018	Phase 2 will include more subjects to further evaluate the safety and efficacy of D-1553 in combination with IN10018 in patients with solid tumors with KRasG12C mutation.

Primary Outcome Measures

Name	Time	Method
adverse events	Through study completion, approximately 3 years	Number of subjects participants with adverse events
Objective response rate (ORR) per RECIST v1.1	Through study completion, approximately 3 years	Defined as the proportion of patients with complete response (CR) or partial response (PR).

Trial Locations

Locations (1)

Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences,; 🇨🇳 Hangzhou, Zhejiang, China